In implementation of directions given in line with review orders issued by the Department of Pharmaceuticals

jftLVªh laö Mhö ,yö&33004@99 REGD. NO. D. L.-33004/99 vlk/kj.k EXTRAORDINARY Hkkx II—[k.M 3—mi&[k.M (ii) PART II—Section 3—Sub-section (ii) izkf/dkj ls izdkf'kr PUBLISHED BY AUTHORITY la- 234] ubZ fnYyh] cq/okj] tuojh 17] 2018@ikS"k 27] 1939 No. 234] NEW DELHI, WEDNESDAY, JANUARY 17, 2018/PAUSHA 27, 1939 jlk;u vkSj moZjd ea=ky; ¼vkS’k/k foHkkx½ jk’Vªh; vkS’k/k ewY; fu/kkZj.k izkf/kdj.k vkns’k ub Z fnYyh] 16 tuojh] 2018 ddddkkkk----vvvvkkkk---- 222266669999¼¼¼¼vvvv½½½½.—vkS"k/k foHkkx }kjk vkS”k/k ¼ewY; fu;a=.k½] 2013 ds iSjk 31 ds varxZr ikfjr blesa uhps lkj.kh ds LraHk ¼6½ esa fofufnZ”V vkns’kksa ds }kjk tkjh iqufoZyksdu vkns’kksa ds lanHkZ esa fn;s x, funsZ’kksa ds dk;kZUo;u esa vkSj Hkkjr ljdkj ds jlk;u vkSj moZjd ea=ky; }kjk tkjh dk0 vk0 1394¼v½ rkjh[k 30 ebZ] 2013 vkSj dk0 vk0 701¼v½ rkjh[k 10 ekpZ] 2016 ds lkFk ifBr vkS”k/k ¼dher fu;a=.k½ vkns’k] 2013 ds iSjk 4, 6, 10, 11, 14, 16, 17 vkSj 18 }kjk iznRr ‘kfDr;ksa dk iz;ksx djrs gq, vkSj lkj.kh ds LraHk ¼7½ esa fofufnZ”V Hkkjr ljdkj ds jlk;u vkSj moZjd ea=ky;] (jk”Vªh; vkS”k/k ewY; fu/kkZj.k izkf/kdj.k) ds vkns’kksa ds vf/kdze.k esa] tgk¡ rd mldk lEcU/k uhps dh lkj.kh ds fofufeZfr iSdksa ls gS] mu ckrksa ds flok;] vf/kØkUr djrs gq, ftUgsa ,sls vf/kØe.k ds iwoZ fd;k x;k gS ;k djus dk yksi fd;k x;k gS] jk"Vªh; vkS"k/k ewY; fu/kkZj.k izkf/kdj.k ¼ftldks laf{kIr :i esa ,uihih, dgk tkrk gS½ uhps dh lkj.kh ds LraHk ¼5½ esa fofufnZ”V vf/kdre dher dks mDr lkj.kh ds LraHk ¼3½ vkSj ¼4½ esa Øe’k% rRLFkkuh izfof”V;ksa esa fofufnZ”V [kqjkd :i ,oa izcyrk vkSj bdkbZ lfgr ml lkj.kh ds LraHk ¼2½ esa dh rRLFkkuh izfof”V esa fofufnZ”V vuqlwfpr fofufeZfr;ksa esa ls izR;sd ij ykxw oLrq ,oa lsok dj] ;fn dksbZ gS] dks NksM+dj vf/kdre dher ds :i esa fu;r djrh gS% llllkkkkjjjj....kkkkhhhh dz- vuqlwfpr [kqjkd :i ,oa bdkbZ vf/kdre iqufoZyksdu vkns’k ekStwnk dk- vk- la- ,oa la- fofufeZfr dk izcyrk dher la- ,oa rkjh[k rkjh[k uke ¼#-½ (1) (2) (3) (4) (5) (6) (7) 1. ,u&,flVkbyflLVhulpsr 200 fexzk- 1 8.16 31015/07/2017- 2058(v) fnukad xzke ewY; fu/kkZj.k dh 30.06.2017 fnukad (Ø-la- 408) 338 GI/2018 (1)2 THE GAZETTE OF INDIA : EXTRAORDINARY [PART II—SEC. 3(ii)] 24.07.2017 2. tseflVkckbu batsD’ku ds fy, izfr 1063.15 31015/48/2017- 2058(v) fnukad ikmMj 200 fexzk- iSd ewY; fu/kkZj.k dh 30.06.2017 fnukad (Ø-la- 248) 01.12.2017 3. ,EQksVsfjflu batsD’ku ds fy, izfr 3402.55 31015/43/2017- 2059(v) fnukad ch&fyfiM@ ikmMj 50 fexzk- iSd ewY; fu/kkZj.k dh 30.06.2017 fyikslkseky fnukad (Ø-la- 7) 07.11.2017 31015/45/2017- ewY; fu/kkZj.k dh fnukad 16.11.2017 uksV % ¼d½ ljdkj }kjk bl izdkj fu;r dh xbZ vkSj vf/klwfpr dh xbZ vf/kdre dher ¼/ku oLrq ,oa lsok dj] tks ykxw gksa½ ls vf/kd dher ij vuqlwfpr fofufeZfr;ksa ds czkaMsM ;k tsusfjd ;k nksuksa :ikarjksa dks csp jgs vuqlwfpr fofufeZfr;ksa ds lHkh fofuekZrk] mi;qZDr lkj.kh ds LraHk (5) esa of.kZr vf/kdre dher ¼/ku oLrq ,oa lsok dj] tks ykxw gksa½ ls vf/kd lHkh ,slh fofufeZr;ksa dh dher dk v/kkseq[kh la’kks/ku djsaxsA ¼[k½ mi;qZDr lkj.kh ¼/ku oLrq ,oa lsok dj] tks ykxw gS] ;fn dksbZ gS½ ds LraHk ¼5½ esa fofufnZ”V vf/kdre ewY; dh vis{kk de [kqnjk ewY; okyh Åij of.kZr vuqlwfpr fofufeZfr;ksa ds lHkh ekStwnk fofuekZrk Mhihlhvks] 2013 ds iSjk 13¼2½ ds vuqlkj oLrq ,oa lsok dj ds dk;kZUo;u ij mRikn ‘kqYd vkSj djksa ds varj ds dkj.k vf/kdre [kqnjk ewY; esa gqbZ o`f) ds vykok ekStwnk vf/kdre [kqnjk ewY; dks fujarj cuk, j[ksaxsA ¼x½ vxj fuekZrkvksa us mi;qZDr lkj.kh ds LraHk (5) esa of.kZr vf/kdre dher ij ljdkj dks okLro esa Hkqxrku fd;k gS ;k ;g ns; gS rks os oLrq ,oa lsok dj dks tksM+ ldrs gSaA ¼?k½ vkS"k/k ¼ewY; fu;a=.k½ vkns'k] 2013 ds iSjkxzkQ 11 esa fn, x, izko/kkuksa ds rgr lEcfU/kr fuekZrkvksa dks mi;qZDr lkj.kh ds LraHk ¼5½ esa fofufnZ"V vf/kdre dher ds vk/kkj ij vuqlwfpr fofufeZfr;ksa ds iSdksa ds fy, vf/kdre dher fu/kkZfjr djsaA fuekZrk vkS"k/k ¼ewY; fu;a=.k½ vkns'k] 2013 ds iSjkxzkQ 24 ds rgr QkWeZ&V esa vf/klwpuk dh rkjh[k ls vkbZihMh,e,l ds ek/;e ls Hkjdj ,uihih, dks ,d ewY; lwph tkjh djsa rFkk mldh dkWih jkT; vkS”kf/k fu;a=dksa vkSj fofuekZrk forjdksa dks tkjh djsaA ¼M+½ vkS"k/k ¼ewY; fu;a=.k½ vkns'k] 2013 ds 24 (4) ds mica/kksa ds vuqlkj izR;sd QqVdj fodzsrk vkSj forjd fofuekZrk }kjk fn, x, :i esa ,sls ifjlj] tgka dkjksckj dks bl izdkj fd;k tk jgk gS fd mlls ijke’kZ ds bPNqd fdlh O;fDr ds fy, igqap vklku gks] ogka mlds fdlh lgtn`’; Hkkx ij dher lwph vkSj iwjd lwph] ;fn dksbZ gks] dks laiznf’kZr djsxkA ¼p½ mi;qZDr lkj.kh ds LraHk ¼5½ esa fofufnZ"V vf/kdre dher ds fy, fofufnZ"V vuqlwfpr fofufeZfr;ksa ds fofufnZ"V fofHkUu rjhds vkSj izcyrk ls fHkUu vxj ekStwnk fuekZrkvksa }kjk ,d ubZ vkS"kf/k dks ykap djrk gS rks mls igys vkS"k/k ¼ewY; fu;a=.k½ vkns'k] 2013 ds iSjkxzkQ 2¼;w½ ds vuqlkj vkS"k/k ¼ewY; fu;a=.k½ vkns'k] 2013 ds rgr lwph II esa fofufnZ"V QkeZ I ds ek/;e ls ,uihih, esa ewY; fu/kkZj.k gsrq vkosnu djuk gksxkA ¼N½ mi;qZDr vuqlwfpr fofufeZfr;ksa dh mRiknu@vk;kr vkSj fcØh ds lEcU/k esa fuekZrkvksa dks vkS"k/k ¼ewY; fu;a=.k½ vkns'k] 2013 ds lwph II ds QkWeZ III dks vkbZihMh,e,l ds ek/;e ls Hkjdj ,uihih, dks gj frekgh dh fjiksVZ izLrqr djsxkA mi;qZDr vuqlwfpr fofufeZfr;ksa ds fuekZ.k dks dksbZ fuekZrk mRiknu cUn djus dk bPNqd gks rks bldh lwpuk ,uihih, dks voxr djk;sxkA blds lEcU/k esa vxj vuqlwfpr fofufeZfr;ksa ds mRiknu vkSj vk;kr dks cUn djus dk bPNqd gS rks cUn djus dh frfFk ls N% eghus igys lwph II ds QkWeZ IV esa Hkjdj ,uihih, dks izLrqr djsxkA ¼Tk½ fofuekZrk ;k foi.ku dEiuh] mijksDr dfFkr lkj.kh esa n'kkZ;s vf/kdre ewY; vkSj 'krks± dk ikyu ugha djrh gSa rks os vko';d oLrq,¡ vf/kfu;e] 1955 ds lkFk ifBr Mhihlhvks] 2013 ds izko/kkuksa ds v/khu C;kt lfgr vf/kizHkkfjr jkf'k dks tek djus ds fy, nk;h gksaxsA¹Hkkx IIµ[k.M 3(ii)º Hkkjr dk jkti=k % vlk/kj.k 3 ¼>½ bl vkns'k esa mijksDr lkj.kh ds LraHk ¼2½ esa dh rRLFkkuh izfof"V esa fofufnZ"V ,slh fofufeZfr;ksa ds iSdksa dh vf/kdre dher fu;r gksus ds ifj.kkeLo:i] vf/kdre ;k [kqnjk ewY; fu/kkZfjr vkns'k ;fn dksbZ gks] tks fd bl vkns'k ls iwoZ tkjh gq, gS] Lor% gh vf/kØe.k gks tk;saxsA [dka- la-@184@52/2017@एफ@Qk- la- 8¼52½@2017@Mhih@,uihih,&fMoh-II] cythr flag] lgk;d funs'kd MINISTRY OF CHEMICALS AND FERTILIZERS (Department of Pharmaceuticals) (NATIONAL PHARMACEUTICAL PRICING AUTHORITY) ORDER New Delhi, the 16th January, 2018 S.O. 269(E).—In implementation of directions given in line with review orders issued by the Department of Pharmaceuticals (DOP) vide order(s) specified in column (6) of the table herein below passed by the Department of Pharmaceuticals under para 31 of Drugs (Prices Control) Order, 2013 and in exercise of the powers conferred by paragraphs 4, 6, 10, 11, 14, 16, 17 and 18 of the Drugs (Prices Control) Order, 2013, read with S.O. 1394(E) dated the 30th May, 2013 and S.O. 701(E) dated 10th March, 2016 issued by the Government of India in the Ministry of Chemicals and Fertilizers, and in supersession of the Order(s) of the Government of India in the Ministry of Chemicals and Fertilizers (National Pharmaceutical Pricing Authority) specified in the Column (7) of the table regarding formulation specified in mentioned in the table in so far as it relates to formulation pack mentioned in the table below, except in respect of things done or omitted to be done before such supersession, the National Pharmaceutical Pricing Authority, hereby fixes/revises the price as specified in column (5) of the table herein below as ceiling price exclusive of goods and services tax applicable, if any, in respect of the Scheduled formulation(s) specified in the corresponding entry in column (2) of the said Table with the dosage form & strength and unit specified respectively in the corresponding entries in columns (3) and (4) thereof: TABLE Sl. Name of the Dosage form & Unit Ceiling Review Order Existing SO number and No. Scheduled Strength Price number and date date Formulation (Rs.) (1) (2) (3) (4) (5) (6) (7) 1. N-acetylcysteine Sachet 200mg 1 8.16 31015/7/2017- 2058(E) dated 30.6.2017 (at GM Pricing dated Sl. No. 408) 24.07.2017 2. Gemcitabine Powder for Injection Each 1063.15 31015/48/2017- 2058(E) dated 30.6.2017 (at 200mg Pack Pricing dated Sl. No. 248) 01.12.2017 3. Amphotericin B - Powder for Injection 50 Each 3402.55 31015/43/2017- 2059(E) dated 30.6.2017 (at Lipid/ Liposomal mg Pack Pricing dated Sl. No. 07) 07.9.2017 & 31015/45/2017- Pricing dated 16.11.2017 Note: (a) All manufacturers of scheduled formulations, selling the branded or generic or both the versions of scheduled formulations at a price higher than the ceiling price (plus goods and services tax as applicable) so fixed and notified by the Government, shall revise the prices of all such formulations downward not exceeding the ceiling price specified in column (5) in the above table plus goods and services tax as applicable, if any. (b) All the existing manufacturers of above mentioned scheduled formulations having MRP lower than the ceiling price specified in column (5) in the above table plus goods and services tax as applicable, if any, shall continue to maintain the existing MRP in accordance with paragraph 13 (2) of the DPCO, 2013.4 THE GAZETTE OF INDIA : EXTRAORDINARY [PART II—SEC. 3(ii)] (c) The manufacturers may add goods and services tax only if they have paid actually or if it is payable to the Government on the ceiling price mentioned in column (5) of the above said table. (d) The ceiling price for a pack of the scheduled formulation shall be arrived at by the concerned manufacturer in accordance with the ceiling price specified in column (5) of the above table as per provisions contained in paragraph 11 of the Drugs (Prices Control) Order, 2013. The manufacturer shall issue a price list in Form–V from date of Notification as per paragraph 24 of the DPCO, 2013 to NPPA through IPDMS and submit a copy to State Drug Controller and dealers. (e) As per para 24(4) of DPCO 2013, every retailer and dealer shall display price list and the supplementary price list, if any, as furnished by the manufacturer, on a conspicuous part of the premises where he carries on business in a manner so as to be easily accessible to any person wishing to consult the same. (f) Where an existing manufacturer of scheduled formulation with dosage or strength or both as specified in the above table launches a new drug as per paragraph 2 (u) of the DPCO, 2013 such existing manufacturer shall apply for prior price approval of such new drug to the NPPA in Form I as specified under Schedule-II of the DPCO, 2013. (g) The manufacturers of above said scheduled formulations shall furnish quarterly return to the NPPA, in respect of production / import and sale of scheduled formulations in Form-III of Schedule-II of the DPCO, 2013 through IPDMS. Any manufacturer intending to discontinue production of above said scheduled formulation shall furnish information to the NPPA, in respect of discontinuation of production and / or import of scheduled formulation in Form-IV of Schedule-II of the DPCO, 2013 at least six months prior to the intended date of discontinuation. (h) The manufacturers not complying with the ceiling price and notes specified hereinabove shall be liable to deposit the overcharged amount along with interest thereon under the provisions of the Drugs (Prices Control) Order, 2013 read with Essential Commodities Act, 1955. (i) Consequent to the issue of ceiling prices of such formulations as specified in column (2) of the above table in this notification, the price order(s) fixing ceiling or retail price, if any, issued prior to the above said date of notification, stand(s) superseded. [PN/184/52/2017/F/ F. No. 8(52)/2017/D.P./NPPA-Div.-II] BALJIT SINGH, Assistant Director vkns’k ubZ fnYyh] 16 tuojh] 2018 ddddkkkk----vvvvkkkk---- 222277770000¼¼¼¼vvvv½½½½.—Hkkjr ljdkj ds jlk;u vkSj moZjd ea=ky; }kjk tkjh dk0 vk0 1394¼v½ rkjh[k 30 ebZ] 2013 vkSj dk0 vk0 701¼v½ rkjh[k 10 ekpZ] 2016 ds lkFk ifBr vkS"k/k ¼dher fu;a=.k½ vkns'k] 2013 ds iSjk 5, 11 vkSj 15 }kjk iznRr 'kfDr;ksa dk iz;ksx djrs gq,] jk"Vªh; vkS"k/k ewY; fu/kkZj.k izkf/kdj.k ¼ftldks laf{kIr :i esa ,uihih, dgk tkrk gS½] uhps dh lkj.kh ds LraHk ¼6½ eas fofufnZ"V [kqnjk ewY; dks mDr lkj.kh ds LraHk ¼3½] ¼4½] vkSj ¼5½ eas rRLFkkuh izfof"V;ksa esa fofufnZ"V izcyrk] bdkbZ ¼;wfuV½ vkSj fofuekZrk vkSj foi.ku dEifu;ksa ds uke lfgr LraHk ¼2½ esa dh rRLFkkuh izfof"V esa ls izR;sd dh] oLrq ,oa lsok dj] ;fn dksbZ gS] dks NksM+dj vf/kdre [kqnjk ewY; ds :i esa fu;r djrh gSA lkj.kh dz- vuqlwfpr fofufeZfr dk uke@czkaM dk izcyrk bdkbZ fofuekZrk vkSj [kqnjk la- uke foi.ku daiuh ewY; ¼#-½ (1) (2) (3) (4) (5) (6) 1. XyhesihjkbM $ eSVQksfeZu xksyh izR;sd vfyfir ck;ys;MZ 1 eSllZ foaMykl 4.89 xksyh esa: xksyh ck;ksVsd fy- XyhesihjkbM vkbZih 1 @eSllZ baVkl fexzk-] eSVQksfeZu ,plh,y QkekZL;wfVdYl 850 fexzk- ¼lLVsaM jhfyt izk- fy- QkseZ esa½] 2. XyhesijkbM $ eSVQksfeZu xksyh izR;sd fQYe fyfir 1 eSllZ foaMykl 7.23 ck;ys;MZ xksyh esa: xksyh ck;ksVsd fy- XyhesihjkbM vkbZih 2 @eSllZ baVkl fexzk-] eSVQksfeZu ,plh,y QkekZL;wfVdYl 850 fexzk- ¼lLVsaM jhfyt izk- fy- QkseZ esa½]¹Hkkx IIµ[k.M 3(ii)º Hkkjr dk jkti=k % vlk/kj.k 5 3. fdYuhMkbfiu $ feVksizksyksy xksyh izR;sd fQYe fyfir 1 eSllZ lQsVc 6.98 ck;ys;MZ xksyh esa: xksyh ykbQ fdYuhMkbfiu 10 fexzk-] lkbal@eSllZ feVksizksyksy lqlhusV baVkl vkbZih 23-75 fexzk- ds QkekZL;wfVdYl cjkcj feVksizksyksy VkjVªsV izk- fy- 25 fexzk- ¼bZvkj½) 4. ,fLlVkyksizke$ izR;sd fQYe fyfir xksyh 1 eSllZ ,LlsuV 5.73 Dyksuktsike xksyh ¼lh,u,lihvkj,e esa% ,fLlVkyksizke xksyh QkekZ@eSllZ ,evkbZ,uvkbZ½ vkWDlkysV vkbZih ds ;w,loh fy- cjkcj ,fLlVkyksizke 5 fexzk-] Dyksuktsike vkbZih 0-5 fexzk- 5. lsQ~Vªh,Dlksu lksfM;e ,aM VstkscSDVe izR;sd dkWEchiSd esa% izfr eSllZ esudkbaM 76.69 lksfM;e batsD’ku lsQ~Vªh,Dlksu lksfM;e iSd QkekZ fy- ¼LVsjkby½ ds cjkcj ,ugkbMªkst lsQ~Vªh,Dlksu 500 fexzk- ] VstkscSDVe lksfM;e ¼LVsjhy½ ds cjkxj ,ugkbMªkst VstkscSDVe 62- 5 fexzk-] ,aM ou ,Q,Q,l ,EikWy daVsfuax LVsfjy okWVj QkWj batsD’ku 6. vksYeslkVZu$ ,EyksMhikbu xksyh izR;sd vfyfir xksyh esa% 1 eSllZ ,LlsuV 12.29 ¼fVªfiukse 40½ vksYeslkVZu esMkWDlksfey xksyh QkekZ @eSllZ 40 fexzk-] ,EyksMhikbu yqfiu fy- fclkbysV ds cjkcj ,EyksMhihu 5 fexzk] gkbMªksDyksjksFkkbtkbM 12- 5 fexzk] 7. jkstqoklVkfVu $ ,Lizhu dSIlwy izR;sd gkMZ tsysfVu 1 eSllZ VkWjsZaV 8.78 ¼jkstqdksuZ ,,lih 20 QkWVsZ½ dSIlwy esa% dSIlwy QkekZL;wfVdYl jkstqoklVkfVu dSfY’k;e fy- vkbZih ds cjkcj jkstqoklVkfVu 20 fexzk-] ¼fQYe fyfir xksyh esa½ ,Lizhu vkbZih 150 fexzk- ¼bufVªd fyfir xksyh esa½ 8. jkstqoklVkfVu $ ,Lizhu $ DyksihMksxzsy izR;sd gkMZ tsysfVu 1 eSllZ thds,e 11.70 dSIlwy ¼;wuhLVkj xksYM 10@75½ dSIlwy esa% dSIlwy U;w QkekZ@eSllZ jkstqoklVkfVu dSfY’k;e yscksjsVksfjt fy- vkbZih ds cjkcj jkstqoklVkfVu 10 fexzk-] ¼fiySVl esa½] ,Lizhu vkbZih 75 fexzk- ¼bufVªd fyfir xksyh esa½ DyksfiMksxzsy ckblYQsV ds cjkcj DyksfiMksxzsy 75 fexzk- ¼fiySVl esa½] 9. jkstqoklVkfVu $ ,Lizhu $ DyksihMksxzsy izR;sd gkMZ tsysfVu 1 eSllZ thds,e 11.70 dSIlwy ¼t;jksok xksYM 10½ dSIlwy esa% dSIlwy U;w QkekZ@eSllZ jkstqoklVkfVu dSfY’k;e dSfMyk vkbZih ds cjkcj gsYFkds;j fy-6 THE GAZETTE OF INDIA : EXTRAORDINARY [PART II—SEC. 3(ii)] jkstqoklVkfVu 10 fexzk-] ¼xzkuqysl esa½] ,Lizhu vkbZih 75 fexzk- ¼bufVªd fyfir xksyh esa½] DyksfiMksxzsy ckblYQsV ds cjkcj DyksfiMksxzsy 75 fexzk- ¼2 fQYe fyfir xksyh esa½ 10. jkstqoklVkfVu $ ,Lizhu $ DyksihMksxzsy izR;sd gkMZ tsysfVu 1 eSllZ thds,e 11.70 dSIlwy dSIlwy esa% dSIlwy U;w QkekZ@eSllZ jkstqoklVkfVu dSfY’k;e tqosuVl vkbZih ds cjkcj gsYFkds;j fy- jkstqoklVkfVu 10 fexzk-] ¼xzkuqysl esa½] ,Lizhu vkbZih 75 fexzk- ¼bufVªd fyfir xksyh esa½] DyksfiMksxzsy ckblYQsV ds cjkcj DyksfiMksxzsy 75 fexzk- ¼2 fQYe fyfir xksyh esa½ 11. jkstqoklVkfVu $ ,Lizhu $ DyksihMksxzsy izR;sd gkMZ tsysfVu 1 eSllZ lk;uksdse 11.70 dSIlwy dSIlwy esa% dSIlwy QkekZL;wfVdYl jkstqoklVkfVu dSfY’k;e fy-@eSllZ vkbZih ds cjkcj t;Ml jkstqoklVkfVu 10 fexzk-] gsYFkds;j fy- ¼xzkuqysl esa½] ,Lizhu vkbZih 75 fexzk- ¼fiySVl esa½] DyksfiMksxzsy ckblYQsV ds cjkcj DyksfiMksxzsy 75 fexzk- ¼fiySVl esa½] 12. jkstqoklVkfVu $ ,Lizhu $ DyksihMksxzsy izR;sd gkMZ tsysfVu 1 eSllZ lk;uksdse 11.70 dSIlwy dSIlwy esa% dSIlwy QkekZL;wfVdYl jkstqoklVkfVu dSfY’k;e fy-@eSllZ vkbZih ds cjkcj esudkbaM QkekZ jkstqoklVkfVu 10 fexzk-] fy- ¼fiySVl esa½] ,Lizhu vkbZih 75 fexzk- ¼bufVªd fyfir xksyh esa½] DyksfiMksxzsy ckblYQsV ds cjkcj DyksfiMksxzsy 75 fexzk- ¼fiySVl esa½] 13. jkstqoklVkfVu $ ,Lizhu $ DyksihMksxzsy izR;sd gkMZ tsysfVu 1 eSllZ lk;uksdse 11.70 dSIlwy dSIlwy esa% dSIlwy QkekZL;wfVdYl jkstqoklVkfVu dSfY’k;e fy-@eSllZ vkbZih ds cjkcj dsfMyk jkstqoklVkfVu 10 fexzk-] QkekZL;wfVdYl ,Lizhu vkbZih 75 fexzk-] fy- DyksfiMksxzsy ckblYQsV ds cjkcj DyksfiMksxzsy 75 fexzk- 14. jkstqoklVkfVu $ ,Lizhu $ DyksihMksxzsy izR;sd gkMZ tsysfVu 1 eSllZ I;wjs ,aM 11.70 dSIlwy dSIlwy esa% dSIlwy D;wj gsYFkds;j jkstqoklVkfVu dSfY’k;e izk-fy-@eSllZ vkbZih ds cjkcj tqfcysaV ykbQ jkstqoklVkfVu 10 fexzk-] lkbaflt fy-¹Hkkx IIµ[k.M 3(ii)º Hkkjr dk jkti=k % vlk/kj.k 7 ¼fQYe fyfir xksyh esa½] ,Lizhu vkbZih 75 fexzk- ¼xSlVªksjsfLlVsaV xksyh esa½] DyksfiMksxzsy ckblYQsV ds cjkcj DyksfiMksxzsy 75 fexzk- ¼2 fQYe fyfir xksyh esa½ 15. jkstqoklVkfVu $ ,Lizhu $ DyksihMksxzsy izR;sd gkMZ tsysfVu 1 eSllZ lk;uksdse 11.70 dSIlwy dSIlwy esa% dSIlwy QkekZL;wfVdYl jkstqoklVkfVu dSfY’k;e fy-@ eSllZ vkbZih ds cjkcj bfjt jkstqoklVkfVu 10 fexzk-] ykbQlkbauflt ,Lizhu vkbZih 75 fexzk-] fy- DyksfiMksxzsy ckblYQsV ds cjkcj DyksfiMksxzsy 75 fexzk- 16. jkstqoklVkfVu $ ,Lizhu $ DyksihMksxzsy izR;sd gkMZ tsysfVu 1 eSllZ thds,e 18.00 dSIlwy ¼;wuhLVkj xksYM 20@75½ dSIlwy esa% dSIlwy U;w QkekZ@eSllZ jkstqoklVkfVu dSfY’k;e ;wuhdse vkbZih ds cjkcj yscksjsVksfjt fy- jkstqoklVkfVu 20 fexzk-] ¼fiysVl esa½] ,Lizhu vkbZih 75 fexzk- ¼bufVªd fyfir xksyh esa½ DyksfiMksxzsy ckblYQsV ds cjkcj DyksfiMksxzsy 75 fexzk- ¼fiysVl esa½] 17. jkstqoklVkfVu $ ,Lizhu $ DyksihMksxzsy izR;sd gkMZ tsysfVu 1 eSllZ thds,e 18.00 dSIlwy ¼t;jksok xksYM 10½ dSIlwy esa% dSIlwy U;w QkekZ@eSllZ jkstqoklVkfVu dSfY’k;e dsfMyk vkbZih ds cjkcj gsYFkds;j fy- jkstqoklVkfVu 20 fexzk-] ¼xzkuqysl esa½] ,Lizhu vkbZih 75 fexzk- ¼bufVªd fyfir xksyh esa½ DyksfiMksxzsy ckblYQsV ds cjkcj DyksfiMksxzsy 75 fexzk- ¼nks fQYe fyfir esa½] 18. jkstqoklVkfVu $ ,Lizhu $ DyksihMksxzsy izR;sd gkMZ tsysfVu 1 eSllZ thds,e 18.00 dSIlwy dSIlwy esa% dSIlwy U;w QkekZ@eSllZ jkstqoklVkfVu dSfY’k;e tqosuVl vkbZih ds cjkcj gsYFkds;j fy- jkstqoklVkfVu 20 fexzk-] ¼xzkuqysl esa½] ,Lizhu vkbZih 75 fexzk- ¼bufVªd fyfir xksyh esa½ DyksfiMksxzsy ckblYQsV ds cjkcj DyksfiMksxzsy 75 fexzk- ¼nks fQYe fyfir esa½] 19. jkstqoklVkfVu $ ,Lizhu $ DyksihMksxzsy izR;sd gkMZ tsysfVu 1 eSllZ lk;uksdse 18.00 dSIlwy dSIlwy esa% dSIlwy QkekZL;wfVdYl jkstqoklVkfVu dSfY’k;e fy-@eSllZ vkbZih ds cjkcj t;Ml jkstqoklVkfVu 20 fexzk-] gsYFkds;j fy-8 THE GAZETTE OF INDIA : EXTRAORDINARY [PART II—SEC. 3(ii)] ¼fiysVl esa½] ,Lizhu vkbZih 75 fexzk- ¼bufVªd fyfir xksyh esa½ DyksfiMksxzsy ckblYQsV ds cjkcj DyksfiMksxzsy 75 fexzk- ¼fiysVl esa½] 20. jkstqoklVkfVu $ ,Lizhu $ DyksihMksxzsy izR;sd gkMZ tsysfVu 1 eSllZ lk;uksdse 18.00 dSIlwy dSIlwy esa% dSIlwy QkekZL;wfVdYl jkstqoklVkfVu dSfY’k;e fy-@eSllZ vkbZih ds cjkcj esudkbaM QkekZ jkstqoklVkfVu 20 fexzk-] fy- ¼fiysVl esa½] ,Lizhu vkbZih 75 fexzk- ¼bufVªd fyfir xksyh esa½ DyksfiMksxzsy ckblYQsV ds cjkcj DyksfiMksxzsy 75 fexzk- ¼fiysVl esa½] 21. jkstqoklVkfVu $ ,Lizhu $ DyksihMksxzsy izR;sd gkMZ tsysfVu 1 eSllZ lk;uksdse 18.00 dSIlwy dSIlwy esa% dSIlwy QkekZL;wfVdYl jkstqoklVkfVu dSfY’k;e fy-@eSllZ vkbZih ds cjkcj ykbQLVkj QkekZ jkstqoklVkfVu 20 fexzk-] fy- ¼fiysVl esa½] ,Lizhu vkbZih 75 fexzk- ¼bufVªd fyfir xksyh esa½ DyksfiMksxzsy ckblYQsV ds cjkcj DyksfiMksxzsy 75 fexzk- ¼fiysVl esa½] 22. jkstqoklVkfVu $ ,Lizhu $ DyksihMksxzsy izR;sd gkMZ tsysfVu 1 eSllZ I;wj ,aM 18.00 dSIlwy ¼tqfcjk xksYM 10½ dSIlwy esa% dSIlwy D;wj gsYFkds;j jkstqoklVkfVu dSfY’k;e izk- fy-@eSllZ vkbZih ds cjkcj tqfcysaV ykbQ jkstqoklVkfVu 20 fexzk-] lkbaflt fy- ¼fQYe fyfir xksyh esa½] ,Lizhu vkbZih 75 fexzk- ¼xSlVªksjsfLlVsaV xksyh esa½] DyksfiMksxzsy ckblYQsV ds cjkcj DyksfiMksxzsy 75 fexzk- ¼fQYe fyfir xksyh esa½ 23. jkstqoklVkfVu $ ,Lizhu $ DyksihMksxzsy izR;sd gkMZ tsysfVu 1 eSllZ lk;uksdse 18.00 dSIlwy dSIlwy esa% dSIlwy QkekZL;wfVdYl jkstqoklVkfVu dSfY’k;e fy-@eSllZ vkbZih ds cjkcj bfjt jkstqoklVkfVu 20 fexzk-] ykbZQlkbaflt ,Lizhu vkbZih 75 fexzk-] fy- DyksfiMksxzsy ckblYQsV ds cjkcj DyksfiMksxzsy 75 fexzk- 24. jkstqoklVkfVu $ ,Lizhu $ DyksihMksxzsy izR;sd gkMZ tsysfVu 1 eSllZ lQsVc 18.00 dSIlwy dSIlwy esa% dSIlwy ykbZQlkbaflt jkstqoklVkfVu dSfY’k;e fy-@eSllZ vkbZih ds cjkcj yqfiu fy- jkstqoklVkfVu 20 fexzk-] ¼fQYe fyfir xksyh esa½]¹Hkkx IIµ[k.M 3(ii)º Hkkjr dk jkti=k % vlk/kj.k 9 ,Lizhu vkbZih 75 fexzk- ¼bufVªd fyfir xksyh esa½] DyksfiMksxzsy ckblYQsV ds cjkcj DyksfiMksxzsy 75 fexzk- ¼fQYe fyfir xksyh esa½ 25. oksXyhckWl $ XyhesihjkbM $ eSVQksfeZu izR;sd vfyfir fcys;j 1 eSllZ ,lh,ebZ 6.786 xksyh ¼XyhekbZ ,eoh 1½ xksyh esa% oksXyhckWl xksyh tsusfjdl@eSllZ vkbZih 0-2 fexzk-] MkW jsM~Mht XyhesihjkbM vkbZih 1 yscksjsVksfjt fy- fexzk- ,aM eSVQksfeZu gkbMªksDyksjkbM vkbZih 500 fexzk- ¼,lvkj½ 26. oksXyhckWl $ XyhesihjkbM $ eSVQksfeZu izR;sd vfyfir fcys;j 1 eSllZ ,lh,ebZ 8.571 xksyh ¼XyhekbZ ,eoh 2½ xksyh esa% oksXyhckWl xksyh tsusfjdl@eSllZ vkbZih 0-2 fexzk-] MkW jsM~Mht XyhesihjkbM vkbZih 2 yscksjsVksfjt fy- fexzk- ,aM eSVQksfeZu gkbMªksDyksjkbM vkbZih 500 fexzk- ¼,lvkj½ 27. lsfQDlhe $ vkWQykSDlkflu xksyh izR;sd fQYe fyfir xksyh 1 eSllZ Fkhvksu 9.46 ¼(cid:3)ट(cid:5)सफ़-ओ (cid:11)लस½ esa% lsfQDlhe VªkbZgkbMªsV xksyh QkekZL;wfVdYl ds cjkcj ,ugkbMªkst fy-@eSllZ lu vkbZih 200 fexzk QkekZL;wfVdYl vkWQyksDlkflu vkbZih baMLVªhy fy- 200 fexzk- 28. fVªfIlu$czksesySu$:VkslkbM$fMDyksQsud izR;sd ,ufVªd fyfir 1 eSllZ lk;uksdse 13.85 xksyh ¼oksyhVªk ,utks½ xksyh esa% xksyh QkekZL;wfVdYl fVªfIlu chih 48 fexzk fy-@eSllZ lu czksfeySu 90 fexzk-] QkekZL;wfVdYl :VkslkbM VªkbgkbMªsV baMLVªhy fy- chih 100 fexzk-] fMDyksQsud lksfM;e vkbZih 50 fexzk- 29. fXyDyktkbM $ esVQksfeZu xksyh izR;sd fQYe fyfir xksyh 1 eSllZ esldksV 7.65 ¼th,yts ,ebZ,Dl½ esa% fXyDyktkbM vkbZih xksyh gsYFk lhfjt izk- 60 fexzk- ¼,u eksfMQkbZ fy-@eSllZ fjfyt QkWeZ esa½] ,ysefcd esVQksfeZu ,plh,y 500 QkekZL;wfVdYl fexzk- ¼,DlVsaM fjfyt fy- QkWeZ esa½ 30. jkstqoklVkfVu $ DyksihMksxzsy dSIlwy izR;sd gkMZ tsysfVu 1 eSllZ ekbØks 12.95 ¼Vwjcksokl½ dSIlwy esa% dSIlwy yscl fy- jkstqoklVkfVu dSfY’k;e vkbZih ds cjkcj jkstqoklVkfVu 10 fexzk-] ¼fQYe fyfir xksyh esa½] DyksfiMksxzsy ckblYQsV ds cjkcj DyksfiMksxzsy 75 fexzk- ¼2 fQYe fyfir xksyh esa½ uksV % ¼d½ mi;qZDr nh xbZ fofufnZ"V QkWewZys'ku ds fofuekZrk vFkkZr tks ÞubZ Mªxß Mhihlhvks] 2013 ds iSjkxzkQ 2¼;w½ ds rgr mi;qZDr nh xbZ lkj.kh ds LraHk ¼6½ esa fofufnZ"V [kqnjk ewY; fu/kkZfjr djsaxsA10 THE GAZETTE OF INDIA : EXTRAORDINARY [PART II—SEC. 3(ii)] ¼[k½ vxj fofuekZrk us 30-06-2017 rd dh vof/k ds laca/k esa mi;qZDr lkj.kh ds LraHk ¼6½ esa of.kZr QqVdj dher ij ljdkj dks okLro esa Hkqxrku fd;k gS ;k ;g ns; gS rks os LFkkuh; dj tksM+ ldrs gSaA ¼x½ vkS"k/k ¼ewY; fu;a=.k½ vkns'k] 2013 ds iSjkxzkQ 11 esa fn, x, izko/kkuksa ds rgr fuekZrkvksa dks mi;qZDr lkj.kh ds LraHk ¼6½ esa fofufnZ"V [kqnjk ewY; ds vk/kkj ij vuqlwfpr fofufeZfr;ksa ds iSdksa ds fy, [kqnjk ewY; fu/kkZfjr djsaA fuekZrk vkS"k/k ¼ewY; fu;a=.k½ vkns'k] 2013 ds iSjkxzkQ 24 ds rgr QkWeZ V esa vf/klwpuk dh rkjh[k ls ,d ewY; lwph ,uihih, dks vkbZihMh,e,l ds ek/;e ls tkjh djsaA ¼?k½vkS"k/k ¼ewY; fu;a=.k½ vkns'k] 2013 ds 24 (4) ds mica/kksa ds vuqlkj izR;sd QqVdj fodzsrk vkSj forjd fofuekZrk }kjk fn, x, :i esa ,sls ifjlj] tgka dkjckj dks bl izdkj fd;k tk jgk gS fd mlls ijke’kZ ds bPNqd fdlh O;fDr ds fy, igqap vklku gks] ogka mlds fdlh lgtn`’; Hkkx ij dher lwph vkSj iwjd lwph] ;fn dksbZ gks] dks laiznf’kZr djsxkA ¼M-½ mi;qZDr xSj vf/kdre dher ¼[kqnjk ewY;½ dsoy mi;qZDr fuekZrk@foi.ku ds fy, ykxw gS tSlk fd mUgksaus vkS"k/k ¼ewY; fu;a=.k½ vkns'k] 2013 ds rgr vuqc) ewY; fu/kkZj.k@la'kks/ku ds fy, QkWeZ I ij tek fd;k x;k Fkk vkSj ljdkj }kjk fu/kkZfjr lHkh ykxw oS/kkfud vko';drkvksa dh iwfrZ ds v/khu izklafxd fof/k;ksa@fu;eksa ds vUrxZr tSlk fd dsUnzh;@jkT; ykblsflax vkWFkksfjVh ds l{ke izkf/kdkjh }kjk esU;wQsDpfjax ykblsal eatwjh ds rgr lacaf/kr fofufeZr fuekZrk@foi.ku dEifu;ka tks vuqikyu djrh gSA ¼p½ mi;qZDr fofufeZfr;ksa dh mRiknu@vk;kr vkSj fcØh ds lEcU/k esa lEcfU/kr fuekZrkvksa dks vkS"k/k ¼ewY; fu;a=.k½ vkns'k] 2013 ds vuqlwph II ds QkWeZ III dks vkbZihMh,e,l ds ek/;e ls Hkjdj ,uihih, dks gj frekgh dh fjiksVZ izLrqr djsxkA mi;qZDr fofufeZfr;ksa ds fuekZ.k dks dksbZ fuekZrk mRiknu cUn djus dk bPNqd gks rks bldh lwpuk ,uihih, dks voxr djk;sxkA blds lEcU/k esa vxj fofufeZfr;ksa ds mRiknu vkSj vk;kr dks cUn djus dk bPNqd gS rks cUn djus dh frfFk ls de ls de N% eghus igys lwph II ds QkWeZ IV esa Hkjdj ,uihih, dks izLrqr djsxkA ¼N½ fofuekZrk ;k foi.ku dEiuh] mijksDr fofufeZfr;ksa vkSj fofufnZ"V 'krks± dk ikyu ugha djrh gSa rks os vko';d oLrq,¡ vf/kfu;e] 1955 ds lkFk ifBr Mhihlhvks] 2013 ds izko/kkuksa ds v/khu C;kt lfgr vf/kizHkkfjr jkf'k dks tek djus ds fy, nk;h gksaxsA ¼t½ bl vkns'k esa mijksDr lkj.kh ds LraHk ¼2½ esa dh rRLFkkuh izfof"V esa fofufnZ"V fofufeZfr;ksa ds iSdksa dh [kqnjk ewY; fu;r gksus ds ifj.kkeLo#i]vkns'k tks fd bl vkns'k ls iwoZ tkjh gq, gS] Lor% gh fujLr gks tk;saxsA [dka- la-@184@52/2017@,Q@Qk- la0 8¼52½@2017@Mhih@,uihih,&fMoh-II] cythr flag] lgk;d funs'kd ORDER New Delhi, the 16th January, 2018 S.O. 270(E).—In exercise of the powers conferred by paragraphs 5, 11 and 15 of the Drugs (Prices Control) Order, 2013, read with S.O. 1394(E) dated the 30th May, 2013 and S. O. 701(E) dated 10th March, 2016 issued by the Government of India in the Ministry of Chemicals and Fertilizers, the National Pharmaceutical Pricing Authority (hereinafter referred as NPPA), hereby fixes, the price as specified in column (6) of the table herein below as the retail price, exclusive of goods and services tax, if any, in relation to the formulation specified in the corresponding entry in column (2) of the said Table with the strength, unit and name of manufacturer & marketing company, as specified in the corresponding entries in columns (3), (4) and (5) thereof; TABLE Sl. Name of the Strength Unit Manufacturer & Retail No. Scheduled Marketing Company Price (Rs.) Formulation / Brand Name (1) (2) (3) (4) (5) (6) 1. Glimepiride + Each uncoated Bi- Layered tablet 1 Tablet M/s Windlas Biotech 4.89 Metformin Tablet contains: Ltd. / M/s Intas Glimepiride IP 1mg, Pharmaceuticals Pvt. Metformin HCL IP 850mg (As Ltd.¹Hkkx IIµ[k.M 3(ii)º Hkkjr dk jkti=k % vlk/kj.k 11 sustained release form) 2. Glimepiride + Each uncouted Bi- Layered tablet 1 Tablet M/s Windlas Biotech 7.23 Metformin Tablet contains: Ltd. / M/s Intas Glimepiride IP 2mg, Pharmaceuticals Pvt. Metformin HCL IP 850mg (As Ltd. sustained release form) 3. Cilnidipine + Each film couted Bi- Layered tablet 1 Tablet M/s Safetab Life 6.98 Metoprolol Tablet contains: Science and Marketer Cilnidipine 10mg, /M/s Intas Metoprolol Succinate IP 23.75mg eq. Pharmaceuticals Pvt. to Metoprolol Tartrate 25mg (ER) Ltd. 4. Escitalopram + Each film coated tablet contains: 1 Tablet M/s Accent Pharma / 5.73 Clonazepam Tablet Escitalopram Oxalate IP eq. to M/s USV Limited (CENSPRAM MINI) Esccitalopram 5mg Clonazepam IP 0.5mg 5. Ceftriaxone sodium Each combipack contains: Each M/s Mankind Pharma 76.69 & Tazobactam Ceftriaxone sodium (sterile) eq. to pack Ltd. Sodium Injection anhydrous Ceftriaxone 500mg Tazobactam Sodium (sterile) eq. to anhydrous Tazobactam 62.5mg, And One FFS Ampoule containing Sterile water for injection 5ml 6. Olmesartan + Each uncoated tablet contains: Per M/s Accent Pharma / 12.29 Amlodipine Tablet Olmesartan Medoxomil 40mg, Tablet M/s Lupin Ltd. (Tripinom 40) Amlodipine Besylate eq. to Amlodipine 5mg, Hydrochlorothizide 12.5mg 7. Rosuvastatin + Each hard gelatine capsule contains: 1 M/s Torrent 8.78 Aspirin Capsule Rosuvastatin Calcium eq. to Capsule Pharmaceuticals Ltd. (Rozucorn Asp 20 Rosuvastatin 20mg (As film coated Forte) tablet) Aspirin IP 150mg (as enteric coated tablet) 8. Rosuvastatin + Each hard gelatin capsule contains: 1 M/s GKM New 11.70 Aspirin + Rosuvastatin Calcium IP eq. to Capsule Pharma / M/s Clopidogrel Capsule Rosuvastatin 10mg (As Pellets), Unichem Laboratories (Unistar Gold 10/75) Aspirin IP 75mg (As enteric Coated Ltd. Pellets), Clopidogrel Bisulphate IP eq. to Clopidogrel 75mg (As Pellets) 9. Rosuvastatin + Each hard gelatin capsule contains: 1 M/s GKM New 11.70 Aspirin + Rosuvastatin Calcium IP eq. to Capsule Pharma M/s Cadila Clopidogrel Capsule Rosuvastatin 10mg (As granules), Healthcare Ltd. (Zyrova Gold 10) Aspirin IP 75mg (As enteric Coated Tablets), Clopidogrel Bisulphate IP eq. to Clopidogrel 75mg (As two film coated tablets) 10. Rosuvastatin + Each hard gelatin capsule contains: 1 M/s GKM New 11.70 Aspirin + Rosuvastatin Calcium IP eq. to Capsule Pharma / M/s Clopidogrel Capsule Rosuvastatin 10mg (As granules), Zuventus Healthcare Aspirin IP 75mg (As enteric Coated Limited Tablets), Clopidogrel Bisulphate IP eq. to Clopidogrel 75mg (As two film coated tablets) 11. Rosuvastatin + Each hard gelatin capsule contains: 1 M/s Synokem 11.70 Aspirin + Rosuvastatin Calcium IP eq. to Capsule Pharmaceuticals Ltd Clopidogrel Capsule Rosuvastatin 10mg (As Pellets), /M/s Zydus Healthcare Aspirin IP 75mg (As enteric Coated Limited Pellets),12 THE GAZETTE OF INDIA : EXTRAORDINARY [PART II—SEC. 3(ii)] Clopidogrel Bisulphate IP eq. to Clopidogrel 75mg (As Pellets) 12. Rosuvastatin + Each hard gelatin capsule contains: 1 M/s Synokem 11.70 Aspirin + Rosuvastatin Calcium IP eq. to Capsule Pharmaceuticals Ltd / Clopidogrel Capsule Rosuvastatin 10mg (As Pellets), M/s Mankind Pharma Aspirin IP 75mg (As enteric Coated Limited Pellets), Clopidogrel Bisulphate IP eq. to Clopidogrel 75mg (As Pellets) 13. Rosuvastatin + Each hard gelatin capsule contains: 1 M/s Synokem 11.70 Aspirin + Rosuvastatin Calcium IP eq. to Capsule Pharmaceuticals Ltd / Clopidogrel Capsule Rosuvastatin 10mg, M/s Cadila Aspirin IP 75mg, Pharmaceuticals Clopidogrel Bisulphate IP eq. to Limited Clopidogrel 75mg 14. Rosuvastatin + Each hard gelatin capsule contains: 1 M/s Pure and Cure 11.70 Aspirin + Rosuvastatin Calcium IP eq. to Capsule Healthcare Pvt. Ltd. / Clopidogrel Capsule Rosuvastatin 10mg (As film coated M/s Jubilant Life tablet), Sciences Limited Aspirin IP 75mg (As Gastro – resistant tablet), Clopidogrel Bisulphate IP eq. to Clopidogrel 75mg (As film coated tablet) 15. Rosuvastatin + Each hard gelatin capsule contains: 1 M/s Synokem 11.70 Aspirin + Rosuvastatin Calcium IP eq. to Capsule Pharmaceuticals Ltd / Clopidogrel Capsule Rosuvastatin 10mg, M/s Eris Lifesciences Aspirin IP 75mg, Ltd. Clopidogrel Bisulphate IP eq. to Clopidogrel 75mg 16. Rosuvastatin + Each hard gelatin capsule contains: 1 M/s GKM New 18.00 Aspirin + Rosuvastatin Calcium IP eq. to Capsule Pharma / M/s Unichem Clopidogrel Capsule Rosuvastatin 20mg (As Pellets), Laboratories Ltd. (Unistar Gold 20/75) Aspirin IP 75mg (As enteric Coated Pellets), Clopidogrel Bisulphate IP eq. to Clopidogrel 75mg (As Pellets) 17. Rosuvastatin + Each hard gelatin capsule contains: 1 M/s GKM New 18.00 Aspirin + Rosuvastatin Calcium IP eq. to Capsule Pharma /M/s Cadila Clopidogrel Capsule Rosuvastatin 20mg (As granules), Healthcare Ltd. (Zyrova Gold 20) Aspirin IP 75mg (As enteric Coated Tablets), Clopidogrel Bisulphate IP eq. to Clopidogrel 75mg (As two film coated tablets) 18. Rosuvastatin + Each hard gelatin capsule contains: 1 M/s GKM New 18.00 Aspirin + Rosuvastatin Calcium IP eq. to Capsule Pharma /M/s Zuventus Clopidogrel Capsule Rosuvastatin 20mg (As granules), Healthcare Limited Aspirin IP 75mg (As enteric Coated Tablets), Clopidogrel Bisulphate IP eq. to Clopidogrel 75mg (As two film coated tablets) 19. Rosuvastatin + Each hard gelatin capsule contains: 1 M/s Synokem 18.00 Aspirin + Rosuvastatin Calcium IP eq. to Capsule Pharmaceuticals Ltd Clopidogrel Capsule Rosuvastatin 20mg (As Pellets), /M/s Zydus Healthcare Aspirin IP 75mg (As enteric Coated Limited Pellets), Clopidogrel Bisulphate IP eq. to Clopidogrel 75mg (As Pellets) 20. Rosuvastatin + Each hard gelatin capsule contains: 1 M/s Synokem 18.00¹Hkkx IIµ[k.M 3(ii)º Hkkjr dk jkti=k % vlk/kj.k 13 Aspirin + Rosuvastatin Calcium IP eq. to Capsule Pharmaceuticals Ltd/ Clopidogrel Capsule Rosuvastatin 20mg (As Pellets), M/s Mankind Pharma Aspirin IP 75mg (As enteric Coated Limited Pellets), Clopidogrel Bisulphate IP eq. to Clopidogrel 75mg (As Pellets) 21. Rosuvastatin + Each hard gelatin capsule contains: 1 M/s Synokem 18.00 Aspirin + Rosuvastatin Calcium IP eq. to Capsule Pharmaceuticals Ltd Clopidogrel Capsule Rosuvastatin 20mg (As Pellets), /M/s Lifestar Pharma Aspirin IP 75mg (As enteric Coated Limited Pellets), Clopidogrel Bisulphate IP eq. to Clopidogrel 75mg (As Pellets) 22. Rosuvastatin + Each hard gelatin capsule contains: 1 M/s Pure and Cure 18.00 Aspirin + Rosuvastatin Calcium IP eq. to Capsule Healthcare Pvt. Ltd. Clopidogrel Capsule Rosuvastatin 20mg (As film coated /M/s Jubilant Life (Jubira Gold 20) tablet), Sciences Limited Aspirin IP 75mg (As Gastro – resistant tablet), Clopidogrel Bisulphate IP eq. to Clopidogrel 75mg (As film coated tablet) 23. Rosuvastatin + Each hard gelatin capsule contains: 1 M/s Synokem 18.00 Aspirin + Rosuvastatin Calcium IP eq. to Capsule Pharmaceuticals Ltd Clopidogrel Capsule Rosuvastatin 20mg, /M/s Eris Lifesciences Aspirin IP 75mg, Ltd. Clopidogrel Bisulphate IP eq. to Clopidogrel 75mg 24. Rosuvastatin + Each hard gelatin capsule contains: 1 M/s Safetab 18.00 Aspirin + Rosuvastatin Calcium IP eq. to Capsule Lifescience M/s Lupin Clopidogrel Capsule Rosuvastatin 20mg (As film coated Limited tablet), Aspirin IP 75mg (As enteric coated tablet), Clopidogrel Bisulphate IP eq. to Clopidogrel 75mg (As film coated tablet) 25. Voglibose + Each uncoated bilayer tablets 1 Tablet M/s ACME Generics / 6.786 Glimeperide + contains: M/s Dr. Reddy's Metformin Tablet Voglibose IP 0.2mg, Glimeperide IP Laboratories Limited (Glimy MVI) 1mg & Metformin Hydrochloride IP 500mg (SR) 26. Voglibose + Each uncoated bilayer tablet contains: 1 Tablet M/s ACME Generics / 8.571 Glimeperide + Voglibose IP 0.2mg, Glimeperide IP M/s Dr. Reddy's Metformin Tablet 2mg & Metformin Hydrochloride IP Laboratories Limited (Glimy MV2) 500mg (SR) 27. Cefixime + Each film coated tablet contains: 1 Tablet M/s Theon 9.46 Ofloxacin Tablet Cefixime Trihydrate eq. to Cefixime Pharmaceuticals (Ranixime Plus) A n h y d rous IP 200mg, Limited a/ M/s Sun Ofloxacin IP 200mg Pharmaceutical Industrial Limited 28. Trypsin + Bromelain Each enteric coated tablet contains: 1 Tablet M/s Synokem 13.85 + Trypsin BP 48mg, Bromelain Pharmaceuticals Rutoside + 90mg, Limited / M/s Sun Diclofenac Tablet Rutoside Trihydrate BP 100mg Pharmaceuticals (Volitra Enzo) D i c lofenac Sodium IP 50mg Industries Limited 29. Gliclazide + Each film coated tablet contains: 1 Tablet M/s Mascot Health 7.65 Metformin Tablet Gliclazide IP 60mg (In modified Seris Pvt. Ltd. / M/s (GLZ MEX) release form), Metformin HCL Alembic 500mg (extended release form) Pharmaceuticals14 THE GAZETTE OF INDIA : EXTRAORDINARY [PART II—SEC. 3(ii)] Limited 30. Rosuvastatin Each hard gelatine capsule contains: 1 M/s Micro Labs 12.95 +Clopidogrel Rosuvastatin Calcium IP eq. to Capsule Limited Capsule Rosuvastatin 10mg (as film coated (Turbovas C) tablet),Clopidogrel Bisulphate IP eq. to Clopidogrel 75mg (as 2 film coated tablet) Note: (a) The manufacturer of above mentioned formulations i.e. “new drug” under paragraph 2(u) of the DPCO, 2013 shall fix the retail price as specified in column (6) of the table hereinabove. (b) The manufacturer may add goods and services tax only if they have paid actually or it is payable to the Government on the retail price mentioned in column (6) of the above said table. (c) The retail price for a pack of the aforesaid formulation shall be arrived at by the concerned manufacturer in accordance with the retail price specified in column (6) of the above table as per provisions contained in paragraph 11 of the DPCO, 2013. The manufacturer shall issue a price list in Form–V from date of Notification as per paragraph 24 of the DPCO, 2013 to NPPA through IPDMS and submit a copy to State Drug Controller and dealers. (d) As per para 24(4) of DPCO 2013, every retailer and dealer shall display price list and the supplementary price list, if any, as furnished by the manufacturer, on a conspicuous part of the premises where he carries on business in a manner so as to be easily accessible to any person wishing to consult the same. (e) The above mentioned retail price is applicable only to the individual manufacturer / marketeer as mentioned above i.e. who have applied for the same by submitting Form-I for price fixation / revision as stipulated under DPCO, 2013 and subject to fulfilment of all the applicable statutory requirements as laid down by the Govt. under relevant statutes/ rules, including manufacturing license permission from the Competent Authority i.e. the Central/State Licensing Authority, as may be applicable, by the concerned manufacturer/marketing companies. (f) The concerned manufacturer of above said formulations shall furnish quarterly return to the NPPA, in respect of production / import and sale of product in Form-III of Schedule-II of the DPCO, 2013 through IPDMS. Manufacturer, in case intending to discontinue above said formulations, shall furnish information to the NPPA, in respect of discontinuation of the production and / or import of above said formulation in Form-IV of Schedule-II of the DPCO, 2013 at least six months prior to the intended date of discontinuation. (g) In case the retail price of any of the aforesaid formulations is not complied with, as per instant price notification and notes specified hereinabove, then the concerned manufacturer/marketing company shall be liable to deposit the overcharged amount along with the interest thereon under the provisions of the DPCO, 2013 read with the Essential Commodities Act, 1955. (h) Consequent to the issue of ceiling price of such formulation as specified in column (2) of the above table in this notification, the price order(s) fixing ceiling or retail price, if any, issued prior to the above said date of notification, stand(s) superseded. [PN/184/52/2017/F/F. No. 8(52)/2017/D.P./NPPA-Div.-II] BALJIT SINGH, Assistant Director vkns’k ub Z fnYyh] 16 tuojh] 2018 dk-vk- 271¼v½.—vkS"k/k foHkkx }kjk vkS”k/k ¼ewY; fu;a=.k½] 2013 ds iSjk 31 ds varxZr ikfjr 31015@67@2017 fnukad 14 uoacj] 2017 esa fofufnZ”V vkns’kksa ds }kjk tkjh iqufoZyksdu vkns’kksa ds lanHkZ esa fn;s x, funsZ’kksa ds dk;kZUo;u esa vkSj Hkkjr ljdkj ds jlk;u vkSj moZjd ea=ky; }kjk tkjh dk0 vk0 1394¼v½ rkjh[k 30 ebZ] 2013 vkSj dk0 vk0 701¼v½ rkjh[k 10 ekpZ] 2016 ds lkFk ifBr vkS”k/k ¼dher fu;a=.k½ vkns’k] 2013, jk"Vªh; vkS"k/k ewY; fu/kkZj.k izkf/kdj.k fuEufyf[kr fofufeZfr ls lacaf/kr viuk vkns’k 1526¼v½ fnukad 11 ebZ] 2017 dks rRdky izHkko ls jn~n djrh gS%&¹Hkkx IIµ[k.M 3(ii)º Hkkjr dk jkti=k % vlk/kj.k 15 1-,fjFkzksekbflu bLVksysV xksyh 250 fexzk- 2-,fjFkzksekbflu bLVksysV xksyh 500 fexzk- 3-,fjFkzksekbflu bLVksysV flji 125fexzk-@5fefy- 4-DyksjksD;wbu QksLQsV batsD’ku 40 fexzk-@fefy- ¼64-5 fexzk- cjkcj 40 fexzk- DyksjksD;wbu½ [dka- la-@184@52@2017@,Q@Qk- la0 8¼52½@2017@Mhih@,uihih,&fMoh-II] cythr flag] lgk;d funs'kd ORDER New Delhi, the 16th January, 2018 S.O. 271(E).—In implementation of directions given in line with review orders issued by the Department of Pharmaceuticals (DOP) vide order number 31015/67/2017dated 14th November 2017 passed by the Department of Pharmaceuticals under para 31 of Drugs (Prices Control) Order, 2013 read with S.O. 1394(E) dated the 30th May, 2013 and S.O. 701(E) dated 10th March, 2016 issued by the Government of India in the Ministry of Chemicals and Fertilizers, the National Pharmaceutical Pricing Authority, hereby set aside its notification bearing number S.O. 1526(E) dated 11th May 2017 regarding the following formulations with immediate effect: 1. Erythromycin Estolate Tablet 250 mg 2. Erythromycin Estolate Tablet 500 mg 3. Erythromycin Estolate Syrup 125 mg / 5 ml 4. Chloroquine Phosphate Injection 40 mg / ml (64.5mg eq. to 40 mg chloroquine) [PN/184/52/2017/F/F. No. 8(52)/2017/D.P./NPPA-Div.-II] BALJIT SINGH, Assistant Director Uploaded by Dte. of Printing at Government of India Press, Ring Road, Mayapuri, New Delhi-110064 and Published by the Controller of Publications, Delhi-110054.